与NK细胞相关的长非编码RNA揭示了结直肠癌免疫微环境的异质性
Yuxuan Li1, Chuqi Xia1, Jinze Li1
1Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Frontiers in immunology
|December 1, 2025
概括
这项研究开发了一个16个长的非编码RNA (lncRNA) 签名来预测结直肠癌 (CRC) 的结果. 这种预后模型增强了针对CRC患者的NK细胞基础免疫疗法策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 结肠直肠癌 (CRC) 由于预后不佳和对常规治疗的反应有限,造成了重大挑战.
- 基于自然杀手 (NK) 细胞的免疫疗法是治疗CRC的一个有希望的途径.
- 识别预测生物标志物对于优化CRC治疗策略至关重要.
研究的目的:
- 开发和验证使用NK相关的长非编码RNAs (lncRNAs) 的结直肠癌 (CRC) 预后模型.
- 在CRC中确定增强NK细胞基础免疫疗法的新分子标.
主要方法:
- 集成的单细胞RNA测序和TCGA转录组数据,以识别NK特异性的lncRNAs.
- 采用单变Cox,LASSO和多变Cox回归分析来构建一个16-lncRNA预后特征.
- 使用培训,验证集和独立的临床样本验证了模型的预测准确性.
主要成果:
- 一个强大的16-lncRNA预后签名在CRC中表现出高的预测准确性.
- 已确定lncRNA AC010319.3通过降低IFN-γ和B种子酶的调节来抑制NK细胞细胞毒性.
- 这种抑制促进了CRC细胞的增殖和入侵,突出了瘤微环境中的一个关键机制.
结论:
- 与NK相关的lncRNA在CRC免疫微环境中起着重要的调节作用.
- 开发的预后签名为分层CRC患者进行免疫治疗提供了有价值的工具.
- 这些发现为推进CRC免疫疗法提供了新的分子标.
相关概念视频
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs
3.5K
3.5K
Non-LTR Retrotransposons
13.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.1K


